Welcome to our dedicated page for Pharma-Bio Serv SEC filings (Ticker: PBSV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharma-Bio Serv filings document formal disclosures for a consulting firm serving regulated life-science and allied product industries. Its Form 8-K reports furnish operating results and financial-condition updates through earnings releases, while definitive proxy materials cover annual meeting matters, director elections, stockholder voting procedures, board governance and independent auditor ratification. The filings also reflect the company’s public reporting framework for an OTCQB-traded issuer.
Pharma-Bio Serv, Inc. reported an insider equity award for Chairman and director Kirk Michel. On January 10, 2026, he received a stock option covering 20,000 shares of common stock at an exercise price of $0.54 per share, expiring on January 10, 2031. The option vests in two equal installments on July 10, 2026 and July 10, 2027, meaning half of the option becomes exercisable on each of those dates.
Pharma-Bio Serv, Inc. reported a routine insider equity award for director Dov Perlysky. On January 10, 2026, he was granted a stock option covering 20,000 shares of common stock at an exercise price of $0.54 per share. The option vests in two equal installments on July 10, 2026 and July 10, 2027, and expires on January 10, 2031. Following this grant, Perlysky beneficially owns 20,000 derivative securities directly in the form of this option.
Pharma-Bio Serv, Inc. director Howard Spindel reported a new stock option grant. On January 10, 2026, he was awarded 20,000 stock options with an exercise price of $0.54 per share, each option corresponding to one share of common stock.
The options vest in two equal installments on July 10, 2026 and July 10, 2027, meaning half become exercisable on each of those dates. Following this grant, Spindel beneficially owns 20,000 derivative securities, held directly, according to the report.
Pharma-Bio Serv, Inc. director Irving L. Wiesen reported a new stock option grant on a Form 4. On January 10, 2026, he received a stock option for 20,000 shares of Pharma-Bio Serv common stock. The option has an exercise price of $0.54 per share and an expiration date of January 10, 2031.
According to the filing, the option vests in two equal installments on July 10, 2026 and July 10, 2027. After this grant, Wiesen beneficially owns 20,000 derivative securities related to these options, held in direct ownership.
Pharma-Bio Serv, Inc. filed a current report to disclose that it issued a press release announcing its results of operations for the three and nine months ended July 31, 2025. The press release is furnished as Exhibit 99.1 to the report, providing the detailed financial and operating results for that period. The company clarifies that this information, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to certain liability provisions under the Exchange Act or automatically incorporated into other securities filings. The report is signed on behalf of the company by Pedro J. Lasanta, its Chief Financial Officer, Vice President Finance and Administration, and Secretary.
Pharma-Bio Serv, Inc. filed a current report to disclose that it issued a press release announcing its results of operations for the three and nine months ended July 31, 2025. The press release is furnished as Exhibit 99.1 to the report, providing the detailed financial and operating results for that period. The company clarifies that this information, including Exhibit 99.1, is furnished rather than filed, meaning it is not subject to certain liability provisions under the Exchange Act or automatically incorporated into other securities filings. The report is signed on behalf of the company by Pedro J. Lasanta, its Chief Financial Officer, Vice President Finance and Administration, and Secretary.
Pharma-Bio Serv, Inc. (PBSV) discloses share counts, tax items, repurchases and customer concentration. The company reports 10,000,000 authorized shares with 23,519,672 issued and 22,920,442 outstanding at July 31, 2025, and notes 599,230 common shares held in treasury at that date. Under U.S. tax reforms, a 100% exemption on certain foreign-source dividends is noted while GILTI subjects foreign subsidiary earnings to a reduced U.S. tax rate of 10.5%. The Transition Tax payment period runs eight years through the companys second quarter of fiscal 2026. The Spanish subsidiary tax rate is 25%. During the period, the company repurchased 536,258 and 498,557 common shares for aggregate amounts of $507,112 and $484,871, respectively, and paid $1,719,918 on March 20, 2025. Revenue concentration from certain global affiliated groups rose to 53.8% for the nine months ended July 31, 2025, and amounts due from those affiliates represented 55.3% of total accounts receivable at July 31, 2025.
Pharma-Bio Serv, Inc. (PBSV) discloses share counts, tax items, repurchases and customer concentration. The company reports 10,000,000 authorized shares with 23,519,672 issued and 22,920,442 outstanding at July 31, 2025, and notes 599,230 common shares held in treasury at that date. Under U.S. tax reforms, a 100% exemption on certain foreign-source dividends is noted while GILTI subjects foreign subsidiary earnings to a reduced U.S. tax rate of 10.5%. The Transition Tax payment period runs eight years through the companys second quarter of fiscal 2026. The Spanish subsidiary tax rate is 25%. During the period, the company repurchased 536,258 and 498,557 common shares for aggregate amounts of $507,112 and $484,871, respectively, and paid $1,719,918 on March 20, 2025. Revenue concentration from certain global affiliated groups rose to 53.8% for the nine months ended July 31, 2025, and amounts due from those affiliates represented 55.3% of total accounts receivable at July 31, 2025.